ALSO NOTED: Barr gets FDA's blessing for generic Taxol; Biovail founder wants to reform company's board;

> Barr Pharmaceuticals got the FDA's final nod for its generic version of the Bristol-Myers Squibb cancer med Taxol. Report

> Biovail founder and minority shareholder Eugene Melnyk (photo) says he plans to propose changes to the company's board in the wake of a fourth-quarter loss of $32 million. Report

> Bentley Pharmaceuticals posted a 28 percent hike in fourth-quarter revenues. Report

> Abbott Laboratories got FDA approval for an implant that continually tracks blood sugar. Report

> In February the FDA approved nine first-time generic meds, including versions of the osteoporosis med Fosamax, the cancer drug Camptosar, and the heartburn remedy Pepcid Complete. Chart

> Wyeth and Progenics were handed a serious blow yesterday when their intravenous drug methylnaltrexone for postoperative ileus flunked the first of two Phase III trials. Report

> An expert panel will weigh in on Amgen's Nplate. Report

> An FDA committee has unanimously recommended Schering-Plough's sugammadex for approval. Report

> In 2007, there was much ado about the slow pace of new molecular entity (NME) approvals. Though over 200 drugs were approved in 2007, only 19 of them represented groundbreaking advances in medicine. In 2008, according to a post on Pharmalot, the industry is set to repeat last year's lackluster performance. Report

And Finally... Life expectancy in the U.S. is rising, but only among people with more than 12 years of education. Release

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.